170 related articles for article (PubMed ID: 28960868)
1. Mimicking Intermolecular Interactions of Tight Protein-Protein Complexes for Small-Molecule Antagonists.
Xu D; Bum-Erdene K; Si Y; Zhou D; Ghozayel MK; Meroueh SO
ChemMedChem; 2017 Nov; 12(21):1794-1809. PubMed ID: 28960868
[TBL] [Abstract][Full Text] [Related]
2. Small Molecules Engage Hot Spots through Cooperative Binding To Inhibit a Tight Protein-Protein Interaction.
Liu D; Xu D; Liu M; Knabe WE; Yuan C; Zhou D; Huang M; Meroueh SO
Biochemistry; 2017 Mar; 56(12):1768-1784. PubMed ID: 28186725
[TBL] [Abstract][Full Text] [Related]
3. A new class of orthosteric uPAR·uPA small-molecule antagonists are allosteric inhibitors of the uPAR·vitronectin interaction.
Liu D; Zhou D; Wang B; Knabe WE; Meroueh SO
ACS Chem Biol; 2015 Jun; 10(6):1521-34. PubMed ID: 25671694
[TBL] [Abstract][Full Text] [Related]
4. Chemical Space Overlap with Critical Protein-Protein Interface Residues in Commercial and Specialized Small-Molecule Libraries.
Si Y; Xu D; Bum-Erdene K; Ghozayel MK; Yang B; Clemons PA; Meroueh SO
ChemMedChem; 2019 Jan; 14(1):119-131. PubMed ID: 30548204
[TBL] [Abstract][Full Text] [Related]
5. Small-Molecule Inhibition of the uPAR ⋅ uPA Interaction by Conformational Selection.
Xu D; Bum-Erdene K; Leth JM; Ghozayel MK; Ploug M; Meroueh SO
ChemMedChem; 2021 Jan; 16(2):377-387. PubMed ID: 33107192
[TBL] [Abstract][Full Text] [Related]
6. Small molecule antagonists of the urokinase (uPA): urokinase receptor (uPAR) interaction with high reported potencies show only weak effects in cell-based competition assays employing the native uPAR ligand.
De Souza M; Matthews H; Lee JA; Ranson M; Kelso MJ
Bioorg Med Chem; 2011 Apr; 19(8):2549-56. PubMed ID: 21454081
[TBL] [Abstract][Full Text] [Related]
7. The effects of amino-acid mutations on specific interactions between urokinase-type plasminogen activator and its receptor: Ab initio molecular orbital calculations.
Tsuji S; Kasumi T; Nagase K; Yoshikawa E; Kobayashi H; Kurita N
J Mol Graph Model; 2011 Aug; 29(8):975-84. PubMed ID: 21605990
[TBL] [Abstract][Full Text] [Related]
8. Ab initio molecular orbital calculations on specific interactions between urokinase-type plasminogen activator and its receptor.
Nagase K; Kobayashi H; Yoshikawa E; Kurita N
J Mol Graph Model; 2009 Aug; 28(1):46-53. PubMed ID: 19403319
[TBL] [Abstract][Full Text] [Related]
9. Identification of specific sites involved in ligand binding by photoaffinity labeling of the receptor for the urokinase-type plasminogen activator. Residues located at equivalent positions in uPAR domains I and III participate in the assembly of a composite ligand-binding site.
Ploug M
Biochemistry; 1998 Nov; 37(47):16494-505. PubMed ID: 9843416
[TBL] [Abstract][Full Text] [Related]
10. Photoaffinity labeling of the human receptor for urokinase-type plasminogen activator using a decapeptide antagonist. Evidence for a composite ligand-binding site and a short interdomain separation.
Ploug M; Ostergaard S; Hansen LB; Holm A; Danø K
Biochemistry; 1998 Mar; 37(11):3612-22. PubMed ID: 9521680
[TBL] [Abstract][Full Text] [Related]
11. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
Magdolen V; Bürgle M; de Prada NA; Schmiedeberg N; Riemer C; Schroeck F; Kellermann J; Degitz K; Wilhelm OG; Schmitt M; Kessler H
Biol Chem; 2001 Aug; 382(8):1197-205. PubMed ID: 11592401
[TBL] [Abstract][Full Text] [Related]
12. Stabilizing a flexible interdomain hinge region harboring the SMB binding site drives uPAR into its closed conformation.
Zhao B; Gandhi S; Yuan C; Luo Z; Li R; Gårdsvoll H; de Lorenzi V; Sidenius N; Huang M; Ploug M
J Mol Biol; 2015 Mar; 427(6 Pt B):1389-1403. PubMed ID: 25659907
[TBL] [Abstract][Full Text] [Related]
13. Ab initio molecular simulations for proposing novel peptide inhibitors blocking the ligand-binding pocket of urokinase receptor.
Mizushima T; Sugimoto T; Kasumi T; Araki K; Kobayashi H; Kurita N
J Mol Model; 2014 Jun; 20(6):2292. PubMed ID: 24859527
[TBL] [Abstract][Full Text] [Related]
14. Piptide Chemotypes for Perturbation of the Interaction of Urokinase with Its Receptor.
Arancillo M; Lin CM; Burgess K
J Med Chem; 2022 Oct; 65(19):12925-12932. PubMed ID: 36166370
[TBL] [Abstract][Full Text] [Related]
15. Probing binding and cellular activity of pyrrolidinone and piperidinone small molecules targeting the urokinase receptor.
Mani T; Liu D; Zhou D; Li L; Knabe WE; Wang F; Oh K; Meroueh SO
ChemMedChem; 2013 Dec; 8(12):1963-77. PubMed ID: 24115356
[TBL] [Abstract][Full Text] [Related]
16. A Computational Investigation of Small-Molecule Engagement of Hot Spots at Protein-Protein Interaction Interfaces.
Xu D; Si Y; Meroueh SO
J Chem Inf Model; 2017 Sep; 57(9):2250-2272. PubMed ID: 28766941
[TBL] [Abstract][Full Text] [Related]
17. A systematic methodology for large scale compound screening: A case study on the discovery of novel S1PL inhibitors.
Deniz U; Ozkirimli E; Ulgen KO
J Mol Graph Model; 2016 Jan; 63():110-24. PubMed ID: 26724452
[TBL] [Abstract][Full Text] [Related]
18. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR.
Plesner T; Behrendt N; Ploug M
Stem Cells; 1997; 15(6):398-408. PubMed ID: 9402652
[TBL] [Abstract][Full Text] [Related]
19. Dynamics of urokinase receptor interaction with Peptide antagonists studied by amide hydrogen exchange and mass spectrometry.
Jørgensen TJ; Gårdsvoll H; Danø K; Roepstorff P; Ploug M
Biochemistry; 2004 Nov; 43(47):15044-57. PubMed ID: 15554712
[TBL] [Abstract][Full Text] [Related]
20. [Effect of vacuum-assisted closure on the expression of urokinase-type plasminogen activator and urokinase-type plasminogen activator receptor in acute and chronic wounds healing].
Li YJ; Cao DY; Chen SZ
Zhonghua Zheng Xing Wai Ke Za Zhi; 2006 Jul; 22(4):306-9. PubMed ID: 17017150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
